Predicting the dopamine D₂ receptor occupancy of ropinirole in rats using positron emission tomography and pharmacokinetic–pharmacodynamic modeling

References

• Adamiak U, Kaldonska M, Klodowska-Duda G, et al. (2010). Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease. Clin Neuropharmacol 33:135–41
   PubMed Web of Science ®Google Scholar
• Administration USFaD. 1997. Requip NDA 20658. U.S. Food and Drug Administration. Approval Letter
   Google Scholar
• Association CM. 2014. Chinese guidelines for Parkinson's disease treatment (3rd edition). Chinese Journal of Neurology
   Google Scholar
• Atsumi M, Kawakami J, Sugiyama E, et al. (2003). Pharmacokinetic and pharmacodynamic analyses, based on dopamine D2-receptor occupancy of bromocriptine, of bromocriptine-induced contralateral rotations in unilaterally 6-OHDA-lesioned rats. Synapse 50:110–16
   PubMed Web of Science ®Google Scholar
• Barrett JS, Mcguire J, Vezina H, et al. (2013). PET Measurement of Receptor Occupancy as a Tool to Guide Dose Selection in Neuropharmacology: Are We Asking the Right Questions? J Clin Psychopharmacol 33:725
   PubMed Web of Science ®Google Scholar
• Clark-Papasavas C, Dunn JT, Greaves S, et al. (2014). Towards a therapeutic window of D2/3 occupancy for treatment of psychosis in Alzheimer's disease, with [18F]fallypride positron emission tomography. Int J Geriatr Psychiatry 29:1001–9
   PubMed Web of Science ®Google Scholar
• Deleu D, Northway M, Hanssens Y. (2002). Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. Clin Pharmacokinet 41:261–309
   PubMed Web of Science ®Google Scholar
• Deutschlander A, Fougere CL, Xiong G, et al. (2012). Therapeutic occupancy of the D2/3-preferring dopamine receptor agonist pramipexol in brains of patients with Parkinson's disease ([18F]-Fallypride PET Study) (P03.126). Neurology 78:P03–126. P03
   Web of Science ®Google Scholar
• Eden RJ, Costall B, Domeney AM, et al. (1991). Preclinical pharmacology of ropinirole (SK&F 101468-A) a novel dopamine D2 agonist. Pharmacol Biochem Behav 38:147–54
   PubMed Web of Science ®Google Scholar
• Farde L, Nordstrom AL, Wiesel FA, et al. (1992). Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 49:538–44
   PubMed Web of Science ®Google Scholar
• Fukuzaki K, Kamenosono T, Nagata R. (2000). Effects of ropinirole on various parkinsonian models in mice, rats, and cynomolgus monkeys. Pharmacol Biochem Behav 65:503
   PubMed Web of Science ®Google Scholar
• Gancevici G, Toporan M. (2006). The striatal and extrastriatal D2/D3 receptor-binding profile of clozapine in patients with schizophrenia. Neuropsychopharmacology 31:1027–35
   PubMed Web of Science ®Google Scholar
• Gründer G, Fellows C, Janouschek H, et al. (2008). Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study. Am J Psychiatry 165:988–95
   PubMed Web of Science ®Google Scholar
• Grunder G, Landvogt C, Vernaleken I, et al. (2006). The striatal and extrastriatal D2/D3 receptor-binding profile of clozapine in patients with schizophrenia. Neuropsychopharmacology 31:1027–35
   PubMed Web of Science ®Google Scholar
• Ichise M, Meyer JH, Yonekura Y. (2001). An introduction to PET and SPECT neuroreceptor quantification models. J Nucl Med 42:755–63
   PubMed Web of Science ®Google Scholar
• Kapur S, Remington G, Zipursky RB, et al. (1995). The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. Life Sci 57:PL103–7
   PubMed Web of Science ®Google Scholar
• Kim E, Howes OD, Kim BH, et al. (2012). Predicting brain occupancy from plasma levels using PET: superiority of combining pharmacokinetics with pharmacodynamics while modeling the relationship. J. Cereb. Blood Flow Metab 32:759–68
   PubMed Web of Science ®Google Scholar
• Lammertsma AA, Hume SP. (1996). Simplified reference tissue model for PET receptor studies. Neuroimage 4:153–8
   PubMed Web of Science ®Google Scholar
• Lim HS, Su JK, Noh YH, Lee BC, et al. (2013). Exploration of optimal dosing regimens of haloperidol, a D2 antagonist, via modeling and simulation analysis in a D2 receptor occupancy study. Pharm Res 30:683–93
   PubMed Web of Science ®Google Scholar
• Lindstrom ML, Bates DM. (1990). Nonlinear mixed effects models for repeated measures data. Biometrics 46:673–87
   PubMed Web of Science ®Google Scholar
• Matheson AJ, Spencer CM. (2000). Ropinirole: a review of its use in the management of Parkinson's disease. Drugs 60:115–37
   PubMed Web of Science ®Google Scholar
• Mukherjee J, Yang ZY, Das MK, Brown T. (1995). Fluorinated benzamide neuroleptics-III. Development of (S)-N-[(1-allyl-2-pyrrolidinyl)methyl]-5-(3-[18F]fluoropropyl)-2, 3-dimethoxybenzamide as an improved dopamine D-2 receptor tracer. Nucl Med Biol 22:283–96
   PubMed Web of Science ®Google Scholar
• Nakatani Y, Suzuki M, Tokunaga M, et al. (2013). A small-animal pharmacokinetic/pharmacodynamic PET study of central serotonin 1A receptor occupancy by a potential therapeutic agent for overactive bladder. Plos One 8:e75040
   PubMed Web of Science ®Google Scholar
• Nordstrom AL, Farde L, Wiesel FA, et al. (1993). Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol. Psychiatry 33:227–35
   PubMed Web of Science ®Google Scholar
• Ota M, Ogawa S, Kato K, et al. (2015). Striatal and extrastriatal dopamine release in the common marmoset brain measured by positron emission tomography and [(18)F]fallypride. Neurosci Res 101:1–5
   PubMed Web of Science ®Google Scholar
• Passchier J, Gee A, Willemsen A, et al. (2002). Measuring drug-related receptor occupancy with positron emission tomography. Methods 27:278–86
   PubMed Web of Science ®Google Scholar
• Potkin SG, Keator DB, Kesler-West ML, et al. (2014). D2 receptor occupancy following lurasidone treatment in patients with schizophrenia or schizoaffective disorder. Cns Spectrums 19:176–81
   PubMed Web of Science ®Google Scholar
• Ramji JV, Keogh JP, Blake TJ, et al. (1999). Disposition of ropinirole in animals and man. Xenobiotica 29:311–25
   PubMed Web of Science ®Google Scholar
• Rascol O, Brooks DJ, Korczyn AD, et al. (2000). A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med 342:1484
   PubMed Web of Science ®Google Scholar
• Seeman P, Corbett DR, Tol HHMV. (1997). Atypical neuroleptics have low affinity for dopamine D2 receptors or are selective for D4 receptors. Neuropsychopharmacology 16:93–110
   PubMed Web of Science ®Google Scholar
• Seeman P, Tallerico T. (1999). Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine. Am J Psychiatry 156:876
   PubMed Web of Science ®Google Scholar
• Slifstein M, Kegeles LS, Xu X, et al. (2010). Striatal and extrastriatal dopamine release measured with PET and [(18)F] fallypride. Synapse 64:350
   PubMed Web of Science ®Google Scholar
• Swagzdis JE, Wittendorf RW, DeMarinis RM, Mico BA. (1986). Pharmacokinetics of dopamine-2 agonists in rats and dogs. J Pharm Sci 75:925–8
   PubMed Web of Science ®Google Scholar
• Tsartsalis S, Moulinsallanon M, Dumas N, et al. (2014). A modified simplified reference tissue model for the quantification of dopamine D2/3 receptors with [18F]Fallypride images. Mol Imag 13:1–14
   Web of Science ®Google Scholar
• Tulloch IF. (1997). Pharmacologic profile of ropinirole: a nonergoline dopamine agonist. Neurology 49:58–62
   PubMed Web of Science ®Google Scholar
• Vautier S, Milane A, Fernandez C, et al. (2008). Interactions between antiparkinsonian drugs and ABCB1/P-glycoprotein at the blood-brain barrier in a rat brain endothelial cell model. Neurosci Lett 442:19
   PubMed Web of Science ®Google Scholar
• Wang ZT, Huang CR, Xu QQ, Liu SB, Miao LY, (2015). Pharmacokinetics of ropinirole determined by LC-MS/MS in rat plasma and striatum. Chin J New Drugs 24:7
   Google Scholar
• Yang M, Pan D, Xu Y, et al. (2008). Preparation of dopamine D2 receptor imaging agent F-Fallypride and biodistribution study in mice. Nucl Tech 31:360–3
   Google Scholar
• Zhang YM, Fox GB. (2012). PET imaging for receptor occupancy: meditations on calculation and simplification. J Biomed Res 26:69–76
   PubMedGoogle Scholar
• Zhang ZX, Roman GC, Hong Z, et al. (2005). Parkinson's disease in China: prevalence in Beijing, Xian, and Shanghai. Lancet 365:595–7
   PubMed Web of Science ®Google Scholar